Forecasts

▶ 94% Will a publicly available AI model achieve a score of 60.0% or higher on the Virology Capabilities Test (VCT) by December 31, 2027? PASS ITNSSS78 Imp70

Quality92

Ambiguity92

Soon75

Sudden65

Sharp80

Priority scores (ITN + Soon/Sudden/Sharp) Stage 2c

Priority78

Neglectedness85

Tractability85

Neglectedness: Web searches across Metaculus, Polymarket, Manifold, and INFER (as of April 2026) confirm that while the Virology Capabilities Test (VCT) is cited in academic and safety reports (e.g., International AI Safety Report 2026, OECD), no active forecasting markets or systematic policy trackers currently monitor this specific 60% threshold https://arxiv.org/abs/2504.16137. Most existing biorisk tracking focuses on broader indicators rather than this specific multimodal benchmark.

Tractability: Skilled forecasters can improve on a naive prior by analyzing historical scaling laws for LLM performance on expert benchmarks (like GPQA or MMLU), tracking compute trends, and monitoring developer-specific safety disclosures. The rich information environment of AI progress makes this highly tractable for research-heavy forecasting https://arxiv.org/abs/2504.16137.

Soon: With current state-of-the-art models already at 43.8% (outperforming most human experts) as of early 2025, the 60% milestone is a highly relevant near-term target likely to be tested by next-generation frontier models before the 2027 deadline https://arxiv.org/abs/2504.16137.

Sudden: While model training is a gradual process, the release of a new frontier model (e.g., a successor to o3) often results in a discrete, 'sudden' jump in benchmark performance that can surprise the policy community.

Sharp: Capability benchmarks in biology are 'sharp' because improvements often happen in private lab settings or via internal model updates before public release. A model crossing a expertise threshold like 60% could occur without a public 'warning shot' or smaller-scale failure that triggers policy intervention https://arxiv.org/abs/2504.16137.

Proto-question Stage 1

Will a publicly available AI model achieve a score of 60% or higher on the Virology Capabilities Test (VCT) (or a successor version using the same methodology) by December 31, 2027?

Why this question? Current state-of-the-art models like OpenAI's o3 have achieved 43.8% on the VCT, which already outperforms 94% of expert virologists [cfc167]. Reaching 60% would represent a significant leap in the model's ability to provide 'tacit' laboratory knowledge that was previously thought to be a human-only barrier. This is a non-trivial milestone that tracks the rapid advancement of dual-use biological capabilities in LLMs.

Paper reference: Virology Capabilities Test (VCT) and Frontier AI model performance [cfc167]

Refined question Stage 2

### Forecasting Question: AI Performance on the Virology Capabilities Test (VCT) Through 2027 Question Title: Will a publicly available AI model achieve a score of 60.0% or higher on the Virology Capabilities Test (VCT) by December 31, 2027? Background: The Virology Capabilities Test (VCT) is a specialized benchmark designed to evaluate the ability of Large Language Models (LLMs) to troubleshoot complex virology laboratory protocols Virology Capabilities Test. Developed by PhD-level virologists, the test consists of 322 multimodal questions (including text and images) that probe "tacit" laboratory knowledge—practical, expert-level information often absent from standard textbooks but critical for successful biological experimentation Virology Capabilities Test Virology Capabilities Test. As of April 1, 2026, the state-of-the-art (SOTA) performance on the VCT is 43.8%, achieved by OpenAI's o3 model Virology Capabilities Test Virology Capabilities Test. This score already exceeds the performance of approximately 94% of human expert virologists tested on the same material Virology Capabilities Test. Crossing the 60% threshold would represent a significant leap in AI capability, potentially signaling that AI systems can provide expert-level guidance on dual-use biological procedures that were previously considered protected by a human "knowledge barrier" Virology Capabilities Test. Resolution Criteria: This question will resolve as YES if, at any point between April 1, 2026, and December 31, 2027, at 23:59 UTC, a publicly available AI model is verified to have achieved a score of 60.0% or higher on the Virology Capabilities Test (VCT) or a qualified successor version. 1. Publicly Available Model: A model is considered "publicly available" if it is accessible to the general public via a web interface (e.g., ChatGPT, Claude.ai, Gemini), a publicly documented API (e.g., OpenAI API, Anthropic API), or if its weights are available for public download (e.g., Llama, Mistral). Models accessible only to internal researchers or government-vetted partners do not count. 2. Successor Version Criteria: If the original VCT (v1.0) is updated or replaced by its original authors (at SecureBio or the Center for AI Safety) before the resolution date, the question will resolve based on the performance on the most recent version (e.g., VCT v2.0), provided it maintains the same core methodology of measuring expert-level troubleshooting of virology protocols through multimodal Q&A Virology Capabilities Test. 3. Verification of Achievement: Achievement of the score must be verified by one of the following: * Publication on the official VCT leaderboard at virologytest.ai Virology Capabilities Test. * A technical report or peer-reviewed paper from the model's developer (e.g., OpenAI, Anthropic, Google DeepMind) citing the VCT score. * An independent evaluation published by a recognized AI safety or evaluation organization (e.g., METR, UK AI Safety Institute, US AI Safety Institute). 4. Resolution Source: The primary source for resolution is the official leaderboard at https://www.virologytest.ai/. In the event the leaderboard is defunct, resolution will rely on the original research paper "Virology Capabilities Test (VCT): A Multimodal Virology Q&A Benchmark" (arXiv:2504.16137) or credible reporting from major outlets (e.g., Reuters, Nature, The New York Times) Virology Capabilities Test Virology Capabilities Test. Start Date: April 1, 2026 Resolution Deadline: December 31, 2027, 23:59 UTC Primary Resolution URL: https://www.virologytest.ai/ Original Research Reference: https://arxiv.org/abs/2504.16137 Virology Capabilities Test

Background

The Virology Capabilities Test (VCT) is a specialized benchmark designed to evaluate the ability of Large Language Models (LLMs) to troubleshoot complex virology laboratory protocols Virology Capabilities Test. Developed by PhD-level virologists, the test consists of 322 multimodal questions (including text and images) that probe "tacit" laboratory knowledge—practical, expert-level information often absent from standard textbooks but critical for successful biological experimentation Virology Capabilities Test Virology Capabilities Test. As of April 1, 2026, the state-of-the-art (SOTA) performance on the VCT is 43.8%, achieved by OpenAI's o3 model Virology Capabilities Test Virology Capabilities Test. This score already exceeds the performance of approximately 94% of human expert virologists tested on the same material Virology Capabilities Test. Crossing the 60% threshold would represent a significant leap in AI capability, potentially signaling that AI systems can provide expert-level guidance on dual-use biological procedures that were previously considered protected by a human "knowledge barrier" Virology Capabilities Test.

Resolution criteria

This question will resolve as YES if, at any point between April 1, 2026, and December 31, 2027, at 23:59 UTC, a publicly available AI model is verified to have achieved a score of 60.0% or higher on the Virology Capabilities Test (VCT) or a qualified successor version. 1. Publicly Available Model: A model is considered "publicly available" if it is accessible to the general public via a web interface (e.g., ChatGPT, Claude.ai, Gemini), a publicly documented API (e.g., OpenAI API, Anthropic API), or if its weights are available for public download (e.g., Llama, Mistral). Models accessible only to internal researchers or government-vetted partners do not count. 2. Successor Version Criteria: If the original VCT (v1.0) is updated or replaced by its original authors (at SecureBio or the Center for AI Safety) before the resolution date, the question will resolve based on the performance on the most recent version (e.g., VCT v2.0), provided it maintains the same core methodology of measuring expert-level troubleshooting of virology protocols through multimodal Q&A Virology Capabilities Test. 3. Verification of Achievement: Achievement of the score must be verified by one of the following: * Publication on the official VCT leaderboard at virologytest.ai Virology Capabilities Test. * A technical report or peer-reviewed paper from the model's developer (e.g., OpenAI, Anthropic, Google DeepMind) citing the VCT score. * An independent evaluation published by a recognized AI safety or evaluation organization (e.g., METR, UK AI Safety Institute, US AI Safety Institute). 4. Resolution Source: The primary source for resolution is the official leaderboard at https://www.virologytest.ai/. In the event the leaderboard is defunct, resolution will rely on the original research paper "Virology Capabilities Test (VCT): A Multimodal Virology Q&A Benchmark" (arXiv:2504.16137) or credible reporting from major outlets (e.g., Reuters, Nature, The New York Times) Virology Capabilities Test Virology Capabilities Test.

Verification scores Stage 3

Quality: 92.0 Ambiguity: 92.0

Quality notes: This version of the question is excellent and superior to the first. By including the clause 'or a successor version using the same methodology,' it proactively addresses the most likely 'data issue': the potential for the VCT to be updated or replaced by the original authors before 2028 https://securebio.substack.com/p/ais-can-provide-expert-level-virology. This ensures the question remains resolvable even as the field evolves. The 60% threshold is a meaningful 'high entropy' milestone that tracks whether AI can overcome the 'tacit knowledge' barrier in virology Virology Capabilities Test.

Ambiguity notes: The question uses a specific, percentage-based benchmark (VCT) with a clear threshold (60.0%) and state-of-the-art context (43.8%) [[2504.16137] Virology Capabilities Test (VCT) - arXiv](https://arxiv.org/abs/2504.16137). It provides a hierarchy of verification sources and clear definitions for 'publicly available' and 'successor version'.

Adversarial review PASS Edge risk: MEDIUM

Assessment: PASS Edge case risk: MEDIUM

ASSESSMENT: PASS REVIEW: The Virology Capabilities Test (VCT) is a real and highly relevant benchmark for evaluating AI capabilities in a high-risk domain. My research confirms that the benchmark was released in early 2025 by reputable organizations including SecureBio and the Center for AI Safety (CAIS) [[2504.16137] Virology Capabilities Test (VCT) - arXiv](https://arxiv.org/abs/2504.16137) Virology Capabilities Test. The current state-of-the-art (SOTA) score of 43.8% by OpenAI's o3 model is accurately reflected in the background text, as is the comparison to human expert performance (approximately 22% average accuracy, with o3 outperforming 94% of experts) [[PDF] A Multimodal Virology Q&A Benchmark](https://www.virologytest.ai/vct_paper.pdf) Virology Capabilities Test. The resolution source (virologytest.ai) is active and maintained by established AI safety organizations, making it likely to remain accessible through 2027 Virology Capabilities Test. The cited arXiv paper (2504.16137) is also a real, published technical report [[2504.16137] Virology Capabilities Test (VCT) - arXiv](https://arxiv.org/abs/2504.16137). While the specific '60% threshold' and the term 'knowledge barrier' appear to be framing devices used by the question author rather than explicit terms from the paper's abstract, they are substantively grounded in the paper's discussion of dual-use risks and the 'tacit knowledge' required for lab work [[2504.16137] Virology Capabilities Test (VCT) - arXiv](https://arxiv.org/abs/2504.16137) [[PDF] A Multimodal Virology Q&A Benchmark](https://www.virologytest.ai/vct_paper.pdf). The 60% target is an appropriate 'stretch' goal for a late-2027 horizon, given that model performance has progressed from ~19% (GPT-4o) to ~44% (o3) in roughly a year Virology Capabilities Test. The question is not trivially 'YES' because improvements in specialized, multimodal lab troubleshooting may face diminishing returns or require significant new data/reasoning breakthroughs. The resolution criteria are robust, including provisions for successor versions of the test. EVIDENCE: https://www.virologytest.ai/, https://arxiv.org/abs/2504.16137, https://securebio.substack.com/p/ais-can-provide-expert-level-virology, https://safe.ai/work/research SUGGESTION:

Edge cases 5 scenarios

OVERALL_RISK: MEDIUM SCENARIO: A model achieves a score of 59.96%, which is rounded to 60.0% in a developer's technical report but remains 59.9% on the official VCT leaderboard. SEVERITY: MEDIUM FIX: Specify that the official leaderboard at virologytest.ai is the final arbiter for the specific percentage, and the score must be explicitly listed as 60.0% or higher. https://www.virologytest.ai/ SCENARIO: A model developer claims a 60%+ score in a technical report, but independent researchers provide evidence that the model was trained on the VCT's publicly available questions (data contamination). SEVERITY: HIGH FIX: Add a clause stating that the score must be achieved on a "held-out" or "private" test set if there is credible evidence of data contamination, or require verification that the model was not trained on the benchmark. https://arxiv.org/abs/2504.16137 SCENARIO: The VCT authors release a "v2.0" that increases the question count from 322 to 600, and a model scores 60% on this new version while scoring significantly lower on the original v1.0. SEVERITY: MEDIUM FIX: Clarify that a "successor version" must be released by the original authors (SecureBio or CAIS) and be documented as being of comparable or greater difficulty than the original v1.0. https://www.virologytest.ai/ SCENARIO: A model achieves the score but is only accessible via a high-cost enterprise API restricted to specific geographic regions or vetted commercial entities. SEVERITY: MEDIUM FIX: Define "publicly available" as accessible to any individual user with a standard (non-enterprise) account and a valid credit card, excluding models restricted by specialized vetting or regional blocks beyond standard export controls. https://www.virologytest.ai/ SCENARIO: A model achieves 60% using a specific "chain-of-thought" (CoT) prompting strategy that is not the default for the public web interface, leading to disputes over whether the "publicly available" model itself reached the threshold. SEVERITY: LOW FIX: Specify that the score can be achieved using any prompting technique (e.g., CoT, few-shot) as long as those techniques are reproducible by a member of the public using the public API or interface. https://arxiv.org/abs/2504.16137

Forecast rationale

Time left: ~21 months (until Dec 31, 2027). Status quo: State-of-the-art performance is currently 43.8% (OpenAI o3), though research notes xAI's Grok-4.1 Thinking has reportedly already achieved a score of 61.0%. Scope: Any public model verified via leaderboard, developer technical report, or independent evaluator. A No outcome would require Grok-4.1's reported score to be unverified or retracted, combined with a severe, unexpected plateau in multimodal reasoning capabilities for all upcoming models (e.g., GPT-5, Claude 4) over the next two years. A Yes outcome is extremely likely given historical base rates; AI benchmarks like GPQA have seen leaps of nearly 50 points in a single year, and the VCT improved by 25 points in just 18 months. With a mere 16.2% gap from o3's score to the 60% threshold, and reports indicating that next-gen models have already crossed it, the trajectory is clear. In terms of bets, I would happily pay 94 cents for a contract that pays out $1 on a Yes, as the threshold is highly likely to be officially verified well before the deadline.

Importance rationale

The question tracks a significant capability jump (from 43.8% to 60%) in a domain (virology) identified as a major biorisk pathway https://arxiv.org/abs/2504.16137. However, the 60% threshold itself is not explicitly defined as a critical 'point of no return' in the source paper, making it a high-quality but secondary indicator of risk progression https://arxiv.org/abs/2504.16137.

Fable 5 second opinion Stage 6f 91% AGREE

Pipeline: 94%→Fable 5: 91%

Question is well-posed: clear threshold, deadline, broad but credible verification paths (leaderboard, developer system cards, independent evals like METR/AISI), and a sensible successor-version clause. The pipeline's 94% is defensible. From a 43.8% SOTA (o3, April 2026), a 16.2-point gain over ~21 months is modest relative to recent benchmark trajectories, and frontier labs routinely report bio-eval scores in system cards, so a verifiable crossing is likely. Two caveats temper full confidence: (1) the cited Grok-4.1 '61%' figure is 'reportedly' and unverified — it should not be load-bearing until it appears on the leaderboard or a technical report; (2) because VCT is a dual-use biosecurity benchmark, developers may deliberately withhold or redact high scores, modestly weakening the verification pathway versus ordinary benchmarks. These pull me slightly below 94%, but not materially. I'd land near 90-91%, well within agreement range.

▶ 24% Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill mandating DNA synthesis screening be signed into law in the United States by December 31, 2027? REVISED ITNSSS83 Imp85

Quality92

Ambiguity95

Soon85

Sudden75

Sharp70

Priority scores (ITN + Soon/Sudden/Sharp) Stage 2c

Priority83

Neglectedness90

Tractability80

Neglectedness: A comprehensive search of Metaculus, Polymarket, INFER, and Manifold as of April 2026 confirmed that there are no active forecasting questions or markets specifically tracking S.3741 or the passage of mandatory DNA synthesis screening legislation AI Can Already Evade DNA Synthesis Screening. Congress's New .... While broader biosecurity topics are occasionally discussed, this specific legislative outcome is not being systematically monitored by the forecasting community AI Can Already Evade DNA Synthesis Screening. Congress's New .... None of the major prediction platforms or specialized policy trackers have operationalized this bill's passage as a discrete forecasting target AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Tractability: Forecasting the passage of this bill requires synthesizing political signals (bipartisan sponsorship by Sens. Cotton and Klobuchar), technical critiques of its provisions (e.g., homology-based vs. functional screening), and legislative hurdles AI Can Already Evade DNA Synthesis Screening. Congress's New .... There is a rich information environment of congressional records and expert policy analysis that a skilled forecaster can exploit to move beyond a simple base rate of bill passage AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Soon: S.3741 was introduced in early 2026 and is currently active in the 119th Congress AI Can Already Evade DNA Synthesis Screening. Congress's New .... The window for legislative action and the time-sensitive nature of the biosecurity gaps it addresses make this a high-priority "soon" risk; the outcome is likely to be determined within the 2027 resolution window AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Sudden: The passage of a bill into law is a discrete state change. While the legislative process is public and visible, the final steps (committee discharge, floor votes, or inclusion in larger packages) can occur rapidly and with limited advance warning to the general public AI Can Already Evade DNA Synthesis Screening. Congress's New ... AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Sharp: The indicator sits in a domain where biosecurity risks can compound silently (e.g., through AI-enabled design) without obvious "warning shots" before a major incident AI Can Already Evade DNA Synthesis Screening. Congress's New .... While voluntary frameworks exist, this bill addresses a "sharp" risk where the first observable failure of the current screening regime could be catastrophic AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Proto-question Stage 1

Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill containing a mandate for DNA synthesis screening be signed into US law by 31st December 2027?

Why this question? The podcast discusses the need for "damage control" and "defusing the bomb" of biological risk [Page 67]. Research reveals that bipartisan legislation (S.3741) was introduced in early 2026 specifically to mandate that gene synthesis providers screen orders for dangerous sequences—a key policy milestone for mitigating AI-enabled biorisks. Its passage would represent a major regulatory response to the threats described.

Paper reference: Biosecurity Modernization and Innovation Act of 2026 (S.3741) provisions regarding DNA synthesis screening.

Refined question Stage 2

### Question Title Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill mandating DNA synthesis screening be signed into law in the United States by December 31, 2027? ### Background As of April 1, 2026, the regulation of synthetic DNA in the United States relies primarily on voluntary frameworks, such as the 2023 HHS Screening Framework Guidance for Providers and Users of Synthetic Nucleic Acids. This guidance encourages providers to screen synthetic nucleic acid orders for "sequences of concern" (SOCs)—sequences that contribute to the pathogenicity or toxicity of regulated or unregulated biological agents HHS Screening Framework Guidance for Synthetic Nucleic Acids. While these guidelines establish best practices for identifying risks, they lack federal enforcement mechanisms, leading to inconsistent industry compliance. To address these gaps, the Biosecurity Modernization and Innovation Act of 2026 (S.3741) was introduced in the U.S. Senate on January 29, 2026, by Senator Tom Cotton (R-AR) and co-sponsored by Senator Amy Klobuchar (D-MN) S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The bill seeks to establish a mandatory regulatory framework overseen by the Secretary of Commerce. Core provisions include requiring "covered providers" to screen all orders against a centralized list of sequences of concern, implementing customer verification protocols, and participating in compliance audits and adversarial "red-team" testing S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... As of March 2026, S.3741 has been referred to the Senate Committee on Commerce, Science, and Transportation. This forecasting question tracks whether the U.S. will transition from a voluntary biosecurity regime to a mandatory, legally enforceable system for DNA synthesis screening before the end of 2027. ### Resolution Criteria This question will resolve as Yes if, between January 1, 2026, and 23:59 UTC on December 31, 2027, the Biosecurity Modernization and Innovation Act of 2026 (S.3741) or a successor bill is "signed into law" by the President of the United States or otherwise enacted via constitutional processes. * DNA Synthesis Screening: Defined as the process of identifying whether a requested or synthesized nucleic acid sequence matches a "Sequence of Concern" (SOC) to prevent the misuse of synthetic biology for creating pathogens or toxins HHS Screening Framework Guidance for Synthetic Nucleic Acids. * Mandatory Requirement: The enacted legislation must contain a provision that makes screening and/or customer verification a legal requirement for "covered providers" (entities synthesizing/selling synthetic nucleic acids or benchtop synthesis equipment), carrying legal or regulatory penalties for non-compliance (e.g., fines or loss of license) S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... * Successor Bill: A bill qualifies as a successor if it originates from the same legislative intent as S.3741, regardless of its final bill number or title (e.g., a House companion bill, a revised version in a subsequent session of the 119th or 120th Congress, or its inclusion in a larger omnibus package), provided it retains the core mandate for DNA synthesis screening. * Signed into Law: This includes the President signing the bill, the bill becoming law without a signature after 10 days while Congress is in session, or Congress successfully overriding a presidential veto. * Resolution Source: The official status and text of the legislation as tracked on Congress.gov for bill S.3741 (119th Congress) or its successors. The "All Actions" and "Text" tabs will be used to verify enactment and the presence of the mandatory screening provision.

Background

As of April 1, 2026, the regulation of synthetic DNA in the United States is transitioning from voluntary frameworks to mandatory requirements. While the 2023 HHS Screening Framework Guidance established best practices, the May 5, 2025, Executive Order, "Improving the Safety and Security of Biological Research," mandated that federal agencies ensure synthetic nucleic acid procurement is conducted through providers adhering to an updated screening framework Improving the Safety and Security of Biological Research. Furthermore, the Executive Order directed the development of a strategy to govern non-federally funded research and mandated the submission of a legislative proposal to address gaps in authority to achieve comprehensive, scalable, and verifiable nucleic acid synthesis screening in non-federally funded settings Improving the Safety and Security of Biological Research. The "Biosecurity Modernization and Innovation Act of 2026" (S.3741), introduced on January 29, 2026, by Senator Tom Cotton (R-AR) and co-sponsored by Senator Amy Klobuchar (D-MN), serves as the legislative vehicle for this administration-backed initiative to extend mandatory screening requirements to the entire industry S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... Improving the Safety and Security of Biological Research. This forecasting question tracks whether the U.S. will successfully enact this mandatory, legally enforceable system for DNA synthesis screening before the end of 2027.

Resolution criteria

This question will resolve as Yes if, between January 1, 2026, and 23:59 UTC on December 31, 2027, the Biosecurity Modernization and Innovation Act of 2026 (S.3741) or a successor bill is "signed into law" by the President of the United States or otherwise enacted via constitutional processes. * DNA Synthesis Screening: Defined as the process of identifying whether a requested or synthesized nucleic acid sequence matches a "Sequence of Concern" (SOC) to prevent the misuse of synthetic biology for creating pathogens or toxins. * Mandatory Requirement: The enacted legislation must contain a provision that makes screening and/or customer verification a legal requirement for "covered providers" (entities synthesizing/selling synthetic nucleic acids or benchtop synthesis equipment). The mandate must apply to all "covered providers" as defined in S.3741, regardless of revenue or organizational size, including both synthesis services and benchtop equipment manufacturers S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The legislation must impose a direct legal obligation on the private-sector providers themselves, rather than solely restricting federal procurement or agency behavior. * Penalties: The penalties for non-compliance must include punitive measures such as civil fines, statutory damages (e.g., as described in Section 4(f) of S.3741), or revocation of operating licenses, rather than just a loss of optional federal funding S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... * Successor Bill: A bill qualifies as a successor if it originates from the same legislative intent as S.3741, regardless of its final bill number or title, provided it retains the core mandate for DNA synthesis screening. The bill must retain a requirement to screen against a comprehensive and evolving list of sequences of concern that includes, but is not limited to, the Pathogens and Toxins of Biosecurity Concern. * Signed into Law: This includes the President signing the bill, the bill becoming law without a signature after 10 days while Congress is in session, or Congress successfully overriding a presidential veto. The legislation qualifies for a YES resolution if it is enacted by the deadline, even if the implementation date or the date on which penalties become enforceable occurs after December 31, 2027. * Resolution Source: The official status and text of the legislation as tracked on Congress.gov for bill S.3741 (119th Congress) or its successors. The "All Actions" and "Text" tabs will be used to verify enactment and the presence of the mandatory screening provision.

Verification scores Stage 3

Quality: 92.0 Ambiguity: 95.0

Quality notes: This is a high-quality legislative forecasting question. It identifies a concrete, bipartisan bill (S.3741, introduced Jan 2026) with a specific biosecurity mandate (DNA synthesis screening) S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... Legislative outcomes are inherently non-trivial and subject to significant expert disagreement, satisfying the 'high entropy' criterion. The resolution source (Congress.gov) is authoritative and persistent. The inclusion of 'successor bills' provides necessary flexibility for legislative drift while maintaining the core policy focus on mandatory screening. This is a very good question for a tournament.

Ambiguity notes: The question is exceptionally well-defined with clear legal terminology and a robust definition of 'successor bill' to handle legislative technicalities. The resolution source (Congress.gov) is authoritative and unambiguous S.3741 - Biosecurity Modernization and Innovation Act of 2026 ....

Adversarial review NEEDS_REVISION Edge risk: MEDIUM

Assessment: NEEDS_REVISION Edge case risk: MEDIUM

ASSESSMENT: NEEDS_REVISION REVIEW: The forecasting question is technically well-defined but contains a significant gap in its background section that affects the framing of the uncertainty. 1. Existence of Bill and Sponsors: The Biosecurity Modernization and Innovation Act of 2026 (S.3741) and its sponsors (Senators Cotton and Klobuchar) are real S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The bill was introduced on January 29, 2026, and includes mandatory screening requirements with civil penalties (up to $750,000 for non-individuals) S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... 2. Current Regulatory Landscape: The background correctly identifies the 2023 HHS Screening Framework as a voluntary guideline https://aspr.hhs.gov/S3/Pages/Synthetic-Nucleic-Acids.aspx. However, it fails to mention the May 5, 2025, Executive Order, "Improving the Safety and Security of Biological Research" Improving the Safety and Security of Biological Research. 3. Substantive Problem: This Executive Order already mandates DNA synthesis screening for all federally funded research and, crucially, directed the OSTP to submit a legislative proposal by November 2025 to cover non-federally funded settings Improving the Safety and Security of Biological Research. S.3741 appears to be the bipartisan legislative vehicle for this administration-backed initiative. 4. Impact on Forecasters: By presenting the bill as a new attempt to fix a "gap" in a "voluntary regime," the background ignores that the transition to a mandatory regime is already official executive policy. This makes the bill more likely to pass (as it has administration support and bipartisan sponsorship) than the current text suggests. The "uncertainty" is less about whether the U.S. wants a mandatory system and more about the legislative timing of a pre-planned policy shift. 5. Resolution Criteria: The criteria for "successor bill" and "mandatory requirement" are objective and provide clear guardrails for resolution S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The use of Congress.gov as a source is appropriate. EVIDENCE: https://www.congress.gov/bill/119th-congress/senate-bill/3741/text, https://aspr.hhs.gov/S3/Pages/Synthetic-Nucleic-Acids.aspx, https://www.whitehouse.gov/presidential-actions/2025/05/improving-the-safety-and-security-of-biological-research/ SUGGESTION: Update the 'Background' section to include the May 5, 2025, Executive Order. Specifically, note that the executive branch has already mandated screening for federally funded projects and that S.3741 serves as the legislative fulfillment of the administration's strategy to extend these mandates to the entire industry. This provides forecasters with the necessary context that the bill is part of an active, bipartisan, and multi-branch policy push rather than a speculative independent proposal.

Edge cases 5 scenarios

OVERALL_RISK: MEDIUM SCENARIO: A bill is passed that mandates DNA synthesis screening but limits the definition of 'covered providers' to only those with annual revenues exceeding $100 million, exempting smaller providers and benchtop synthesis equipment startups. SEVERITY: MEDIUM FIX: Add language to the 'Mandatory Requirement' section stating: 'The mandate must apply to all "covered providers" as defined in S.3741, regardless of revenue or organizational size, including both synthesis services and benchtop equipment manufacturers.' https://www.congress.gov/bill/119th-congress/senate-bill/3741/text SCENARIO: An omnibus spending bill is enacted that requires federal agencies to screen their own synthesis orders but does not impose a legal mandate or penalties on private-sector synthesis providers themselves. SEVERITY: HIGH FIX: Amend the 'Mandatory Requirement' definition to state: 'The legislation must impose a direct legal obligation on the private-sector providers themselves, rather than solely restricting federal procurement or agency behavior.' https://www.congress.gov/bill/119th-congress/senate-bill/3741/text AI Can Already Evade DNA Synthesis Screening. Congress's New ... SCENARIO: A successor bill is enacted that mandates screening for 'pathogens on the Select Agent list' but does not include the broader 'Sequences of Concern' (SOC) framework or the centralized list overseen by the Secretary of Commerce as described in S.3741. SEVERITY: MEDIUM FIX: Add to the 'Successor Bill' definition: 'The bill must retain a requirement to screen against a comprehensive and evolving list of sequences of concern that includes, but is not limited to, the Pathogens and Toxins of Biosecurity Concern.' https://www.congress.gov/bill/119th-congress/senate-bill/3741/text SCENARIO: The legislation is signed into law with a 'mandatory' screening provision, but the effective date of the penalties for non-compliance is set for January 1, 2029, which is after the resolution deadline. SEVERITY: MEDIUM FIX: Clarify in the 'Signed into Law' section: 'The legislation qualifies for a YES resolution if it is enacted by the deadline, even if the implementation date or the date on which penalties become enforceable occurs after December 31, 2027.' AI Can Already Evade DNA Synthesis Screening. Congress's New ... SCENARIO: A bill is enacted that mandates screening but defines the 'penalty' solely as a loss of eligibility for future federal grants, rather than the civil fines or 'statutory damages' specified in S.3741. SEVERITY: HIGH FIX: Modify the 'Mandatory Requirement' section to specify: 'The penalties for non-compliance must include punitive measures such as civil fines, statutory damages (e.g., as described in Section 4(f) of S.3741), or revocation of operating licenses, rather than just a loss of optional federal funding.' https://www.congress.gov/bill/119th-congress/senate-bill/3741/text

Revised question REVISED

### Question Title Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill mandating DNA synthesis screening be signed into law in the United States by December 31, 2027? ### Background As of April 1, 2026, the regulation of synthetic DNA in the United States is transitioning from voluntary frameworks to mandatory requirements. While the 2023 HHS Screening Framework Guidance established best practices, the May 5, 2025, Executive Order, "Improving the Safety and Security of Biological Research," mandated that federal agencies ensure synthetic nucleic acid procurement is conducted through providers adhering to an updated screening framework Improving the Safety and Security of Biological Research. Furthermore, the Executive Order directed the development of a strategy to govern non-federally funded research and mandated the submission of a legislative proposal to address gaps in authority to achieve comprehensive, scalable, and verifiable nucleic acid synthesis screening in non-federally funded settings Improving the Safety and Security of Biological Research. The "Biosecurity Modernization and Innovation Act of 2026" (S.3741), introduced on January 29, 2026, by Senator Tom Cotton (R-AR) and co-sponsored by Senator Amy Klobuchar (D-MN), serves as the legislative vehicle for this administration-backed initiative to extend mandatory screening requirements to the entire industry S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... Improving the Safety and Security of Biological Research. This forecasting question tracks whether the U.S. will successfully enact this mandatory, legally enforceable system for DNA synthesis screening before the end of 2027. ### Resolution Criteria This question will resolve as Yes if, between January 1, 2026, and 23:59 UTC on December 31, 2027, the Biosecurity Modernization and Innovation Act of 2026 (S.3741) or a successor bill is "signed into law" by the President of the United States or otherwise enacted via constitutional processes. * DNA Synthesis Screening: Defined as the process of identifying whether a requested or synthesized nucleic acid sequence matches a "Sequence of Concern" (SOC) to prevent the misuse of synthetic biology for creating pathogens or toxins. * Mandatory Requirement: The enacted legislation must contain a provision that makes screening and/or customer verification a legal requirement for "covered providers" (entities synthesizing/selling synthetic nucleic acids or benchtop synthesis equipment). The mandate must apply to all "covered providers" as defined in S.3741, regardless of revenue or organizational size, including both synthesis services and benchtop equipment manufacturers S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The legislation must impose a direct legal obligation on the private-sector providers themselves, rather than solely restricting federal procurement or agency behavior. * Penalties: The penalties for non-compliance must include punitive measures such as civil fines, statutory damages (e.g., as described in Section 4(f) of S.3741), or revocation of operating licenses, rather than just a loss of optional federal funding S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... * Successor Bill: A bill qualifies as a successor if it originates from the same legislative intent as S.3741, regardless of its final bill number or title, provided it retains the core mandate for DNA synthesis screening. The bill must retain a requirement to screen against a comprehensive and evolving list of sequences of concern that includes, but is not limited to, the Pathogens and Toxins of Biosecurity Concern. * Signed into Law: This includes the President signing the bill, the bill becoming law without a signature after 10 days while Congress is in session, or Congress successfully overriding a presidential veto. The legislation qualifies for a YES resolution if it is enacted by the deadline, even if the implementation date or the date on which penalties become enforceable occurs after December 31, 2027. * Resolution Source: The official status and text of the legislation as tracked on Congress.gov for bill S.3741 (119th Congress) or its successors. The "All Actions" and "Text" tabs will be used to verify enactment and the presence of the mandatory screening provision.

Forecast rationale

There are 639 days left until the Dec. 31, 2027 resolution date. The status quo, if nothing changes, is NO: S.3741 is still only introduced and sitting in Senate Commerce with no hearings or markup yet S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... On a narrow scope of just this standalone bill, the odds are low; historically only about 2-3% of Senate bills become law, and only about 10-20% of referred bills even get a hearing or markup All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... On the broader scope that matters for resolution, a successor bill or an NDAA/omnibus rider makes passage materially more plausible, especially because similar biosecurity language has recently ridden the NDAA, which has passed for 64 straight years The BIOSECURE Act Becomes Law in the United States | Advisories. The main NO case is legislative inertia, crowding by higher-priority issues, and the risk that any eventual compromise adds exemptions or softens obligations enough to fail this question's strict all-covered-providers plus penalties criteria All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ... S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The YES case is unusually strong for a niche bill: bipartisan Cotton/Klobuchar sponsorship, explicit alignment with the 2025 executive order calling for a legislative proposal, likely presidential support if it reaches the desk, and a plausible must-pass vehicle path S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ... The BIOSECURE Act Becomes Law in the United States | Advisories. In betting terms, I would be roughly indifferent between buying YES at 36 cents and NO at 64 cents; above that, I prefer NO because the committee-stage starting point still dominates.

Importance rationale

The Biosecurity Modernization and Innovation Act of 2026 (S.3741) represents a critical regulatory milestone by attempting to mandate DNA synthesis screening, transitioning it from a voluntary to a federally enforceable requirement AI Can Already Evade DNA Synthesis Screening. Congress's New .... This is a leading indicator for the US government's ability to mitigate AI-enabled biorisks, a key concern identified in the source material AI Can Already Evade DNA Synthesis Screening. Congress's New .... Resolution would significantly update beliefs about the trajectory of biosecurity governance and the practical constraints on malicious actors' access to dangerous genetic material AI Can Already Evade DNA Synthesis Screening. Congress's New ....

Fable 5 second opinion Stage 6f 20% AGREE

Pipeline: 24%→Fable 5: 20%

The question is well-posed with detailed, source-anchored resolution criteria and a sensible successor-bill clause. The pipeline's 24% is reasonable and its reasoning is sound: it correctly weights the strong tailwinds (bipartisan Cotton/Klobuchar sponsorship, explicit EO directive to submit legislation, possible NDAA vehicle) against the strict requirement that the 'hard' provisions (punitive penalties, all covered providers regardless of size, benchtop mandates) survive intact. Two factors pull me slightly lower than 24%. First, even bipartisan, administration-backed bills rarely complete enactment within a ~2-year window given a crowded calendar; standalone regulatory bills especially stall. Second, the resolution demands the enacted text retain specific hard provisions — the most common path to passage (a watered-down compromise dropping benchtop/penalty teeth) would resolve NO, and the positive-correlation argument only partially offsets this. The NDAA-rider possibility is the main upside. Net, I'd place it around 18-20%, materially overlapping the pipeline estimate. The 4-point gap is not large enough to warrant disagreement.

Decomposition & Research Stage 6b 2 subquestions

Initial forecast: 36%→Research-informed: 65% (+29pp)

Re-forecast rationale

The enactment of the 'Biosecurity Modernization and Innovation Act of 2026' (S.3741) or a successor by December 31, 2027, has a moderate to high probability due to several reinforcing factors. First, the bill has strong bipartisan sponsorship (Cotton, R-AR; Klobuchar, D-MN), which is a critical indicator for legislative success in a polarized environment. Second, it is directly supported by a May 2025 Executive Order that explicitly mandates the development of a legislative proposal to close gaps in non-federally funded biosecurity screening. This aligns the executive and legislative branches on a unified policy goal. Third, the industry is already moving toward standardized protocols (IGSC transitioning to 50bp thresholds by late 2026), suggesting that the 'regulatory floor' the bill seeks to establish is increasingly viewed as an industry standard rather than a radical new burden. However, there are notable risks. While S.3741 is in the Senate, the House is currently advancing H.R. 3029, a more voluntary, standards-based alternative. Resolving the differences between a mandatory, punitive regulatory framework (Senate) and a voluntary, standards-based framework (House) often leads to legislative delays. Additionally, technical concerns regarding the definition of 'Sequences of Concern' (SOC) and the operational costs of human-in-the-loop review for small providers may invite lobbying efforts to water down the mandates. Given that legislative windows for significant technology regulations are typically 12-24 months, the 21-month window remaining is realistic but leaves little room for major political gridlock. The base rate for bipartisan security bills reaching enactment is favorable, but the transition from voluntary to mandatory remains a contentious hurdle.

SQ1: What are the primary legislative obstacles and milestones for S.3741 and its House companions within the 119th Congress?

Summary: As of April 1, 2026, the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) remains in the early stages of the legislative process in the 119th Congress. Introduced on January 29, 2026, by Senators Tom Cotton (R-AR) and Amy Klobuchar (D-MN), the bill was referred to the Senate Committee on Commerce, Science, and Transportation All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... No hearings or markups have been officially scheduled to date All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... While some sources link the bill to a House companion, H.R. 4242, official records do not yet formally list a related House measure, though a similar but more voluntary bill, H.R. 3029, has already seen committee action in the House S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... The bill's progress will depend on navigating the Commerce committee and potentially competing with less prescriptive biosecurity standards already advancing in the House.

Background: The passage of the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill depends heavily on its ability to clear the legislative hurdles of the 119th Congress. As a bipartisan bill introduced by Senator Tom Cotton (R-AR) and co-sponsored by Senator Amy Klobuchar (D-MN), it has a strong starting position; however, its path to enactment by December 31, 2027, will be influenced by the specific committee assignments (likely Senate Commerce or HELP), the level of support or opposition from House leadership, and the prioritization of biosecurity within the broader legislative calendar. Researching the bill's current status, including any scheduled hearings, markups, or companion legislation in the House (such as H.R. 4242), is essential to determining the speed and likelihood of its progression. Additionally, understanding the positions of key legislative gatekeepers and the historical success rate of similar bipartisan security-focused technology regulations will provide a necessary base rate for this forecast.

Detailed research

The "Biosecurity Modernization and Innovation Act of 2026" (S.3741) was introduced in the Senate by Senator Tom Cotton (R-AR) and Senator Amy Klobuchar (D-MN) on January 29, 2026 All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... The bill was referred to the Senate Committee on Commerce, Science, and Transportation on the same day All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... As of the current date, official legislative records from Congress.gov indicate no scheduled hearings or markups for the bill All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... Regarding the House companion, there is conflicting data. Official Senate records for S.3741 list zero related bills as of early 2026 S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... However, external tracking services and legislative summaries suggest that a House version, H.R. 4242, exists or is associated with the same policy area All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... It is important to note that a separate bill, H.R. 3029 (the "Nucleic Acid Standards for Biosecurity Act"), was introduced earlier in the 119th Congress (April 2025) and has already cleared the House Science Committee, indicating a faster track for standards-based biosecurity measures compared to the regulatory mandates in S.3741 S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... Key gatekeepers include Senator Cotton and Senator Klobuchar, whose bipartisan sponsorship provides a strong foundation All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... However, the bill's focus on mandatory regulations rather than voluntary standards (the approach of H.R. 3029) may face resistance from industry-aligned members in the House. Historical data for similar bipartisan, security-focused tech regulations shows they often require 12-18 months to move from introduction to final passage, placing the December 2027 deadline within a realistic but tight window. | Legislative Milestone | Status (as of April 1, 2026) | Date | | :--- | :--- | :--- | | Senate Introduction (S.3741) | Completed | Jan 29, 2026 | | Senate Committee Referral | Commerce, Science, and Transportation | Jan 29, 2026 | | Senate Hearings/Markups | None scheduled | N/A | | House Companion Status | Identified as H.R. 4242 (unconfirmed by official cross-ref) | N/A | | Competing Legislation | H.R. 3029 (Passed Committee) | April 2025 |

SQ2: How do industry stakeholders and executive branch agencies view the technical and economic feasibility of the mandatory screening requirements in S.3741?

Summary: The "Biosecurity Modernization and Innovation Act of 2026" (S.3741) marks a transition from voluntary to mandatory DNA synthesis screening, a shift that industry stakeholders and executive agencies view as technically complex but economically viable if implemented with regulatory clarity. Industry leaders like the International Gene Synthesis Consortium (IGSC) highlight the lack of a standardized "Sequence of Concern" (SOC) list as a primary technical hurdle, as current taxonomy-based screening is prone to both false positives and evasion by AI-designed sequences [[PDF] IGSC Harmonized Screening Protocol v3.0](https://genesynthesisconsortium.org/wp-content/uploads/IGSC-Harmonized-Screening-Protocol-v3.0-1.pdf) [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). Benchtop manufacturers face unique technical requirements, including the need for secure hardware architectures and internet-connected screening protocols for previously offline devices Securing Benchtop DNA Synthesizers | IFP. Economically, while compliance costs (including PhD-level expert review and hardware certification) are significant, proponents argue that a federal mandate "levels the playing field" and provides a necessary market signal for biosecurity innovation [[PDF] Competitive Compliance: Why Uniform Screening Standards ...](https://ari.us/wp-content/uploads/2026/01/Competitive-Compliance_-Why-Uniform-Screening-Standards-Support-Innovation-and-Thwart-Regulatory-Capture.pdf). Following the May 5, 2025, Executive Order, the Department of Commerce and HHS are tasked with replacing voluntary guidelines with a formal conformity assessment system that includes punitive damages—up to $750,000 per violation—and mandatory 'red-team' testing to ensure system integrity S.3741 - Biosecurity Modernization and Innovation Act of 2026 ... HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk ....

Background: The "Biosecurity Modernization and Innovation Act of 2026" proposes to move DNA synthesis screening from a voluntary framework to a mandatory, legally enforceable system with punitive damages. This shift directly impacts "covered providers," including synthesis service providers and benchtop equipment manufacturers. The feasibility of this mandate depends on the alignment between the bill's requirements and the interests of major industry stakeholders, such as the International Gene Synthesis Consortium (IGSC), and the technical ability of providers to comply without stifling innovation. Research should focus on the specific concerns raised by the biotechnology industry regarding compliance costs, the "Sequence of Concern" (SOC) definition, and potential liabilities. Furthermore, analyzing the executive branch's commitment—specifically how the Department of Commerce and HHS are preparing to implement the mandates directed by the May 5, 2025, Executive Order—will clarify whether the technical and economic framework for the bill is viewed as ready for federal enforcement.

Detailed research

### Industry Stakeholder Perspectives (IGSC and Broad Industry) Industry stakeholders, led by the International Gene Synthesis Consortium (IGSC), have historically favored a voluntary, harmonized screening framework but acknowledge the shift toward mandatory requirements [[PDF] IGSC Harmonized Screening Protocol v3.0](https://genesynthesisconsortium.org/wp-content/uploads/IGSC-Harmonized-Screening-Protocol-v3.0-1.pdf). * Technical Feasibility: The primary technical challenge is the lack of a standardized, internationally agreed-upon 'Sequence of Concern' (SOC) list [[PDF] IGSC Harmonized Screening Protocol v3.0](https://genesynthesisconsortium.org/wp-content/uploads/IGSC-Harmonized-Screening-Protocol-v3.0-1.pdf) [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). Screening currently relies on 'best match' taxonomic hits, which stakeholders argue is insufficient as it misses functional threats and flags benign housekeeping genes [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). As of September 2024, IGSC protocols require transitioning to a 50bp screening threshold by October 2026 to align with federal guidance [[PDF] IGSC Harmonized Screening Protocol v3.0](https://genesynthesisconsortium.org/wp-content/uploads/IGSC-Harmonized-Screening-Protocol-v3.0-1.pdf). * Economic Feasibility: Industry reports from January 2026 suggest mandatory screening is economically viable, with a UK-based study estimating £3.50 in security benefits for every £1 spent [[PDF] Competitive Compliance: Why Uniform Screening Standards ...](https://ari.us/wp-content/uploads/2026/01/Competitive-Compliance_-Why-Uniform-Screening-Standards-Support-Innovation-and-Thwart-Regulatory-Capture.pdf). However, stakeholders note 'negative financial incentives,' where rigorous screening increases operational costs and may drive customers to less-regulated overseas providers [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). ### Benchtop Equipment Manufacturers The "Biosecurity Modernization and Innovation Act of 2026" (S.3741) explicitly includes benchtop manufacturers as 'covered providers' S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... * Technical Feasibility: Manufacturers must move from offline devices to integrated systems capable of secure, cloud-based screening or token-based authentication for air-gapped environments Securing Benchtop DNA Synthesizers | IFP. They are expected to implement the STRIDE security framework (e.g., secure boot, encrypted I/O) to prevent tampering Securing Benchtop DNA Synthesizers | IFP. * Economic Impact: Compliance introduces significant upfront R&D and 'Biosecurity Readiness Certification' (BRC) costs Securing Benchtop DNA Synthesizers | IFP. While these costs strain a low-margin market, proponents argue that regulatory clarity will eventually stimulate innovation by providing a clear 'demand signal' for screening technologies [[PDF] Competitive Compliance: Why Uniform Screening Standards ...](https://ari.us/wp-content/uploads/2026/01/Competitive-Compliance_-Why-Uniform-Screening-Standards-Support-Innovation-and-Thwart-Regulatory-Capture.pdf). ### Executive Branch Implementation (Commerce and HHS) The May 5, 2025, Executive Order ("Improving the Safety and Security of Biological Research") directed a 120-day review to "revise or replace" the 2024 Screening Framework HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk .... * HHS Role: HHS (via ASPR) is the lead for technical guidance. As of late 2025, the agency is in a transitional phase, awaiting the finalized revised framework required by the 2025 EO HHS & OSTP Screening | Synthetic Nucleic Acid Security & Biorisk .... * Commerce Role: S.3741 designates the Secretary of Commerce as the lead for promulgating mandatory regulations within one year of enactment S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... This includes establishing a conformity assessment system and performing 'red-team' adversarial testing to verify compliance S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... ### Sequence of Concern (SOC) Definition Concerns The industry is highly concerned that current SOC definitions are both too broad and too narrow. * Specific Concerns: Stakeholders argue that current homology-based screening is vulnerable to AI-enabled 'biodesign' tools that can create functional homologs with low sequence identity to known pathogens [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). * Industry Demand: There is a strong industry call for a move toward 'function-based' screening and the creation of a government-funded, centralized SOC database to replace the current fragmented system of proprietary databases [[PDF] Strengthening a Safe and Secure Nucleic Acid Synthesis Ecosystem](https://ebrc.org/wp-content/uploads/2025/02/EBRC-2025-Strengthening-a-Safe-and-Secure-Nucleic-Acid-Synthesis-Screening-Ecosystem.pdf). ### Potential Liabilities and Enforcement S.3741 introduces significant legal risks for non-compliance. * Statutory Damages: The bill authorizes the Attorney General to seek civil penalties up to $500,000 for individuals and $750,000 for organizations per violation S.3741 - Biosecurity Modernization and Innovation Act of 2026 .... * Compliance Costs: While the direct cost of screening tools is relatively low, the cost of 'human-in-the-loop' expert review for flagged sequences (often requiring PhD-level staff) is a major operational expense [[PDF] IGSC Harmonized Screening Protocol v3.0](https://genesynthesisconsortium.org/wp-content/uploads/IGSC-Harmonized-Screening-Protocol-v3.0-1.pdf) [[PDF] Competitive Compliance: Why Uniform Screening Standards ...](https://ari.us/wp-content/uploads/2026/01/Competitive-Compliance_-Why-Uniform-Screening-Standards-Support-Innovation-and-Thwart-Regulatory-Capture.pdf). Manufacturers also face liability for failure to prevent sales to embargoed entities, as seen in historical export control cases Securing Benchtop DNA Synthesizers | IFP.

Probabilistic Decomposition Stage 6c 2 components

Structure: Sequential Chain

Formula: P(C1) * P(C2|C1)

C1: Will the "Biosecurity Modernization and Innovation Act of 2026" (S.3741) or a successor bill be signed into law in the United States by December 31, 2027? 40% Expected: 30-50%

Role: First node in a sequential chain. Sets the baseline probability of legislative enactment for the specific bill or its direct successors.

Dependencies: C1 is the primary prerequisite. C2 is conditionally dependent on C1 being true (the passage of a bill). The relationship is strong; if a bill passes, it is likely because the core stakeholders reached a consensus on its stringency, though the risk of 'watering down' during the amendment process is the primary uncertainty captured in C2.

Background

The "Biosecurity Modernization and Innovation Act of 2026" (S.3741) is the primary legislative vehicle for a May 5, 2025, Executive Order aimed at making DNA synthesis screening mandatory. As of April 1, 2026, the bill is in the Senate Committee on Commerce, Science, and Transportation. Its passage depends on overcoming legislative inertia in a divided Congress and navigating the prioritization of biosecurity against other high-profile tech regulations. Historical base rates for bipartisan, security-focused technology legislation suggest a 12-to-18-month window from introduction to enactment is realistic but requires sustained political momentum. This component focuses on the fundamental hurdle of getting the bill (or a successor) through both chambers and signed by the President.

Forecast rationale

The \"Biosecurity Modernization and Innovation Act of 2026\" (S.3741) was introduced on January 29, 2026, by Senators Tom Cotton (R-AR) and Amy Klobuchar (D-MN) All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... As of April 1, 2026, the bill is currently referred to the Senate Committee on Commerce, Science, and Transportation All Info - S.3741 - 119th Congress (2025-2026): Biosecurity ... AI Can Already Evade DNA Synthesis Screening. Congress's New .... The probability of 40% is based on the following factors: 1. Bipartisan Support and Executive Alignment: The bill has strong bipartisan backing from key members of both parties Biosecurity Modernization and Innovation Act of 2026 is a Major Step. Furthermore, it aligns with the May 5, 2025, Executive Order by President Trump, which aimed to improve the safety and security of biological research and mandating DNA synthesis screening Biosecurity Modernization and Innovation Act of 2026 is a Major Step AI Can Already Evade DNA Synthesis Screening. Congress's New .... This alignment between the executive and legislative branches often increases the likelihood of passage. 2. Precedent of Security Legislation: The recent enactment of the BIOSECURE Act on December 18, 2025, as part of the FY2026 National Defense Authorization Act (NDAA), demonstrates that biosecurity and biotech-related national security issues are currently a high priority for Congress. This precedent suggests a "successor bill" or a similar vehicle (like the FY2027 or FY2028 NDAA) could serve as a path for S.3741's provisions if the standalone bill stalls. 3. Legislative Timeline Hurdles: Despite the momentum, the bill is in the early stages of the 119th Congress. Historical base rates for bipartisan technology legislation suggest that while a 12-to-18-month window is realistic, many such bills fail due to legislative inertia or the prioritization of other high-profile issues Biosecurity Modernization and Innovation Act of 2026 is a Major Step AI Can Already Evade DNA Synthesis Screening. Congress's New .... The bill currently lacks scheduled hearings or markups as of April 2026 All Info - S.3741 - 119th Congress (2025-2026): Biosecurity .... 4. Technical and Industry Challenges: Critics have pointed out technical gaps in the bill, such as its reliance on homology-based screening which can be bypassed by AI-designed sequences, and the lack of oversight for benchtop synthesizers after purchase AI Can Already Evade DNA Synthesis Screening. Congress's New .... These technical complexities may lead to prolonged negotiations and revisions, potentially pushing enactment beyond the December 31, 2027, deadline. The estimate tilts slightly toward NO (40%) because, while the political will exists, the typical "bottleneck" of the committee process and the potential for the bill to be crowded out by other legislative priorities in 2027 make the timeline tight for a bill only just introduced. However, the possibility of it being folded into a "successor" must-pass bill like the NDAA keeps the probability significant.

C2: Given that S.3741 or a successor bill is signed into law by December 31, 2027, will the enacted version retain both punitive civil fines for non-compliance and mandatory screening requirements for benchtop synthesis equipment? 45% Expected: 60-80%

Role: Second node in a sequential chain — conditional on C1. This is a 'model-breaking' component because it accounts for the scenario where biosecurity legislation is signed (C1), but fails to trigger a YES for the parent question due to the omission of punitive fines or benchtop coverage.

Dependencies: C2 is evaluated only if C1 is true. There is a positive correlation between 'high-momentum' passage (C1) and 'high-stringency' retention (C2), as a weak consensus might lead to both lower passage odds and a more likely 'watering down' of the provisions.

Background

The parent question requires that any enacted legislation must include punitive civil fines (like the $750,000 per violation in S.3741) and must cover benchtop synthesis equipment manufacturers, regardless of size. Research indicates that a competing bill, H.R. 3029 (Nucleic Acid Standards for Biosecurity Act), has already cleared the House Science Committee but focuses on voluntary standards rather than mandatory, punitive regulations. Additionally, the International Gene Synthesis Consortium (IGSC) and benchtop manufacturers have raised technical concerns regarding the 'Sequence of Concern' (SOC) list and the hardware architectures required for compliance. This 'model-breaking' component asks whether the legislative process will result in a version that actually meets the parent question's strict criteria, or if the bill will be weakened to a voluntary or non-punitive framework to secure passage.

Forecast rationale

The probability that the enacted version of S.3741 (the Biosecurity Modernization and Innovation Act of 2026) or its successor will retain both punitive civil fines and mandatory screening for benchtop equipment is estimated at 45%. As of April 1, 2026, the current legislative text of S.3741 explicitly includes these provisions: it defines 'covered providers' to include manufacturers of 'benchtop synthesizers' [[PDF] S. 3741 - Congress.gov](https://www.congress.gov/119/bills/s3741/BILLS-119s3741is.pdf) [[PDF] A BILL - Senator Tom Cotton](https://www.cotton.senate.gov/imo/media/doc/biosecurity_modernization_and_innovation_act.pdf) and mandates sequence and customer screening protocols [[PDF] S. 3741 - Congress.gov](https://www.congress.gov/119/bills/s3741/BILLS-119s3741is.pdf). Crucially, it specifies punitive statutory damages for non-compliance, capped at $750,000 for non-individuals [[PDF] S. 3741 - Congress.gov](https://www.congress.gov/119/bills/s3741/BILLS-119s3741is.pdf) [[PDF] A BILL - Senator Tom Cotton](https://www.cotton.senate.gov/imo/media/doc/biosecurity_modernization_and_innovation_act.pdf). However, several factors suppress the probability of these strict measures surviving the full legislative process. First, a competing bill, H.R. 3029 (Nucleic Acid Standards for Biosecurity Act), has gained traction by focusing on voluntary, stakeholder-driven standards rather than mandatory regulations, specifically to 'safeguard innovation' [Source: House Science Committee snippet]. Industry groups like the International Gene Synthesis Consortium (IGSC) and benchtop manufacturers have historically raised technical and economic concerns regarding the feasibility of embedded screening in hardware and the potential for regulatory overreach to stifle the domestic biotech market. Legislative history suggests that high-stakes regulatory bills often undergo significant 'watering down'—such as converting mandatory requirements into voluntary ones or replacing high fixed fines with discretionary 'reasonableness' standards—to secure enough bipartisan support to pass both chambers. While the national security framing of S.3741 provides strong momentum, the existence of a viable, voluntary alternative (H.R. 3029) makes a compromise that drops the punitive or mandatory benchtop-specific elements more likely than not.

Reconciled Forecast Stage 6d 24%

Bottom-up: 18%→Dep-adj: 22%→Struct-adj: 22%→Holistic: 25%→Final: 24%

Initial (06): 36%→Research (06b): 65%→Reconciled (06d): 24%

Reconciliation rationale

The bottom-up mechanical estimate (0.40 * 0.45 = 0.18) likely underestimates the outcome due to positive correlation between the political momentum required to pass the bill and the political strength to retain its core provisions. If the bill has enough support to reach the President's desk in a crowded legislative calendar, it is more likely that the 'hard' security provisions (punitive damages and benchtop mandates) which define its purpose have remained intact. Therefore, the dependency-adjusted estimate (22%) is higher. The holistic estimate (25%) is slightly higher still, accounting for the possibility that the bill is folded into an 'omnibus' or 'must-pass' national security package like the NDAA, which historically has higher passage rates than standalone regulatory bills and often preserves specific security-focused mandates. Because the holistic and structure-adjusted estimates are within 10 points (22% and 25%), they are averaged for the final forecast.